Gilead Sciences stock slips to EUR 150.26, down 0.58% premarket
Published on 11/10/2026 at 07:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- Gilead is presenting new clinical and real-world evidence at HIV Glasgow through November 11.
- The program covers long-acting HIV treatment and prevention options, including twice-yearly and once-weekly regimens.
- More than 50 studies, including late-breaking data and two oral presentations, are scheduled for the congress.
Gilead Sciences is entering another important HIV data session as the HIV Glasgow 2026 congress continues through Wednesday, November 11. The company said it would present results from more than 50 studies, including late-breaking data and two oral presentations, across treatment and prevention programs. The announcement is available from Gilead Sciences.
Gilead Sciences stock traded at EUR 150.26 on Lang & Schwarz at 07:54 CET on Tuesday, November 10, 2026, down 0.58% from the Xetra close of Monday, November 9, at EUR 151.14.
HIV Pipeline Takes Center Stage
The congress focuses on long-acting regimens, with Gilead highlighting twice-yearly and once-weekly options in its event preview. The company is also using the meeting to provide updates on strategic initiatives and collaborations in HIV research.
For investors, the presentations provide a near-term readout on the development pipeline beyond Gilead's established HIV portfolio. Clinical evidence, durability and the path toward broader prevention use remain central issues as long-acting therapies compete for adoption.
Gilead Sciences stock remains part of the US pharmaceutical market, with the S&P 500 serving as the broad market benchmark.
